More on MRK
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $115.44 |
|
|||
| Open | $114.64 | ||||
| 52 Wk High | $65.46 | ||||
| 52 Wk Low | $47.97 | ||||
| Day High | $114.94 | ||||
| Day Low | $111.57 | ||||
| P/E | 77.46 | ||||
| EPS | $1.47 | ||||
| Volume | 29,522,568 | ||||
- FDA approves Merck's Capvaxive for children at higher pneumonia risk
- U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
- Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
- Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
- German government to drop variable drug discounting plans - Reuters
- FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Ce
- Merck Animal Health to acquire poultry technology firm TARGAN
- Merck Animal Health to Acquire TARGAN
- Gilead and Merck announce successful HIV treatment trial results
Entities mentioned with MRK
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
